Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER-medicare

Journal of Cancer Epidemiology

Volumn , Issue , 2012, Pages

  Griffiths, Robert I ^a,b   Gleeson, Michelle L ^a   Mikhael, Joseph ^c   Danese, Mark D ^a  

^a Outcomes Insights Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL;

EID: 84866245288     PISSN: 16878558     EISSN: 16878566     Source Type: Journal    
DOI: 10.1155/2012/978391     Document Type: Article

References (47)

1. Hillner B. E., Smith T. J., Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. Journal of Clinical Oncology 2009 27 13 2111 2113 2-s2.0-65549153613 10.1200/JCO.2008.21.0534
2. Bach P. B., Limits on medicare's ability to control rising spending on cancer drugs. The New England Journal of Medicine 2009 360 6 562 633 2-s2.0-59749092456
3. Smith T. J., Hillner B. E., Bending the cost curve in cancer care. The New England Journal of Medicine 2011 364 21 2060 2065 2-s2.0-79957492218 10.1056/NEJMsb1013826
4. Rituxan Timeline,.
5. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C., Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine 2002 346 4 235 242 2-s2.0-0037165261 10.1056/NEJMoa011795 (Pubitemid 34438862)
6. Habermann T. M., Weller E. A., Morrison V. A., Gascoyne R. D., Cassileth P. A., Cohn J. B., Dakhil S. R., Woda B., Fisher R. I., Peterson B. A., Horning S. J., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006 24 19 3121 3127 2-s2.0-33745982067 10.1200/JCO.2005.05.1003 (Pubitemid 46638950)
7. Pfreundschuh M., Trümper L., Österborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P. L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., López- Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology 2006 7 5 379 391 2-s2.0-33646004738 10.1016/S1470-2045(06)70664-7
8. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Fermé C., Tilly H., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010 116 12 2040 2045 2-s2.0-77957200763 10.1182/blood-2010-03- 276246
9. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., Reiser M., Metzner B., Harder H., Hegewisch-Becker S., Fischer T., Kropff M., Reis H. E., Freund M., Wörmann B., Fuchs R., Planker M., Schimke J., Eimermacher H., Trümper L., Aldaoud A., Parwaresch R., Unterhalt M., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma study group. Blood 2005 106 12 3725 3732 2-s2.0-28544435078 10.1182/blood-2005-01-0016 (Pubitemid 41742196)
10. Herold M., Haas A., Srock S., Neser S., Al-Ali K. H., Neubauer A., Dölken G., Naumann R., Knauf W., Freund M., Rohrberg R., Höffken K., Franke A., Ittel T., Kettner E., Haak U., Mey U., Klinkenstein C., Amann M., Von Grünhagen U., Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. Journal of Clinical Oncology 2007 25 15 1986 1992 2-s2.0-34249939116 10.1200/JCO.2006.06.4618 (Pubitemid 46972781)
11. Marcus R., Imrie K., Solal-Celigny P., Catalano J. V., Dmoszynska A., Raposo J. C., Offner F. C., Gomez-Codina J., Belch A., Cunningham D., Wassner-Fritsch E., Stein G., Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology 2008 26 28 4579 4586 2-s2.0-53749085410 10.1200/JCO.2007.13.5376
12. Salles G., Mounier N., de Guibert S., Morschhauser F., Doyen C., Rossi J. F., Haioun C., Brice P., Mahé B., Bouabdallah R., Audhuy B., Ferme C., Dartigeas C., Feugier P., Sebban C., Xerri L., Foussard C., Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 112 13 4824 4831 2-s2.0-58149386408 10.1182/blood-2008-04-153189
13. Griffiths R., Gleeson M., Reyes C., Knopf K., Danese M., Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. American Journal of Hematology 2010 85 12 963 967 2-s2.0-78649521769 10.1002/ajh.21878
14. Danese M. D., Griffiths R. I., Gleeson M., Satram-Hoang S., Knopf K., Mikhael J., Reyes C., An observational study of outcomes after initial infused therapy in medicare patients diagnosed with chronic lymphocytic leukemia. Blood 2011 117 13 3505 3513 2-s2.0-79953710007 10.1182/blood-2010-08-301929
15. Griffiths R., Mikhael J., Gleeson M., Danese M., Dreyling M., Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011 118 18 4808 4816
16. Hornberger J., Reyes C., Lubeck D., Valente N., Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leukemia and Lymphoma 2008 49 2 227 236 2-s2.0-38849090730 10.1080/10428190701769665 (Pubitemid 351200289)
17. Hornberger J. C., Best J. H., Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 103 8 1644 1651 2-s2.0-16844378957 10.1002/cncr.20956 (Pubitemid 40490025)
18. Department of Health U. S., Centers for Medicare Human Services, Medicaid Services,. Medicare Part B Drug Average Sales Price. 2011 ASP Drug Pricing Files, 2011
19. Rituximab package insert,.
20. National Comprehensive Cancer Network,. NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin's Lymphomas V.1.2010
21. Surveillance, Epidemiology, End Results (SEER) Program,., SEERStat Database: IncidenceSEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (20002008)Linked To County AttributesTotal U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission
22. Surveillance, Epidemiology, End Results (SEER) Program,., SEERStat Database: IncidenceSEER 9 Regs Research Data, Nov 2010 Sub (19732008)Katrina/ Rita Population Adjustment>Linked To County AttributesTotal U.S., 19692009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission
23. Medicare Payment Advisory Commission (Medpac),. June 2011, A Data Book: Health Care Spending and the Medicare Program
24. Groot M. T., Lugtenburg P. J., Hornberger J., Huijgens P. C., Uyl-De Groot C. A., Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in the Netherlands. European Journal of Haematology 2005 74 3 194 202 2-s2.0-14044263505 10.1111/j.1600-0609.2004.00368.x (Pubitemid 40278488)
25. Best J. H., Hornberger J., Proctor S. J., Omnes L. F., Jost F., Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value in Health 2005 8 4 462 470 2-s2.0-24944512372 10.1111/j.1524-4733.2005.00037.x (Pubitemid 41726099)
26. Ferrara F., Ravasio R., Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clinical Drug Investigation 2008 28 1 55 65 2-s2.0-37249071776 (Pubitemid 350274401)
27. Johnston K. M., Marra C. A., Connors J. M., Najafzadeh M., Sehn L., Peacock S. J., Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value in Health 2010 13 6 703 711 2-s2.0-77956386558 10.1111/j.1524-4733.2010.00737.x
28. Ray J. A., Carr E., Lewis G., Marcus R., An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value in Health 2010 13 4 346 357 2-s2.0-77954270246 10.1111/j.1524-4733.2009.00676.x
29. Griffiths R. I., Gleeson M. L., Mikhael J. R., Danese M. D., Long-term direct medical costs in patients diagnosed with follicular lymphoma who receive frontline chemotherapy with versus without rituximaba SEER-medicare analysis. Proceedings of the ISPOR 16th Annual International Meeting May 2011 Baltimore, Md, USA
30. Warren J. L., Klabunde C. N., Schrag D., Bach P. B., Riley G. F., Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care 2002 40 8 IV-3 IV-18 2-s2.0-0038478965
31. National Cancer Institute,. Overview of the SEER Program, Bethesda, Md, USA, National Cancer Institute
32. National Cancer Institute,. Overview of the SEER Program, Bethesda, Md, USA: National Cancer Institute, 2011
33. North American Association of Central Cancer Registries, Guidelines for ICD-O-3 Implementation 2000
34. Klabunde C. N., Potosky A. L., Legler J. M., Warren J. L., Development of a comorbidity index using physician claims data. Journal of Clinical Epidemiology 2000 53 12 1258 1267 2-s2.0-0034531923 10.1016/S0895-4356(00)00256- 0 (Pubitemid 32007842)
35. Klabunde C. N., Legler J. M., Warren J. L., Baldwin L. M., Schrag D., A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Annals of Epidemiology 2007 17 8 584 590 2-s2.0-34547096275 10.1016/j.annepidem.2007.03.011 (Pubitemid 47096709)
36. Solal-Céligny P., Roy P., Colombat P., White J., Armitage J. O., Arranz-Saez R., Au W. Y., Bellei M., Brice P., Caballero D., Coiffier B., Conde-Garcia E., Doyen C., Federico M., Fisher R. I., Garcia-Conde J. F., Guglielmi C., Hagenbeek A., Haïoun C., LeBlanc M., Lister A. T., Lopez-Guillermo A., McLaughlin P., Milpied N., Morel P., Mounier N., Proctor S. J., Rohatiner A., Smith P., Soubeyran P., Tilly H., Vitolo U., Zinzani P. L., Zucca E., Montserrat E., Follicular lymphoma international prognostic index. Blood 2004 104 5 1258 1265 2-s2.0-4444326818 10.1182/blood-2003-12-4434 (Pubitemid 39166497)
37. Davidoff A. J., Tang M., Seal B., Edelman M. J., Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010 28 13 2191 2197 2-s2.0-77952311362 10.1200/JCO.2009.25.4052
38. Yabroff K. R., Lamont E. B., Mariotto A., Warren J. L., Topor M., Meekins A., Brown M. L., Cost of care for elderly cancer patients in the United States. Journal of the National Cancer Institute 2008 100 9 630 641 2-s2.0-44049106563 10.1093/jnci/djn103
39. Lin D. Y., Linear regression analysis of censored medical costs. Biostatistics 2000 1 35 47
40. Bang H., Tsiatis A. A., Estimating medical costs with censored data. Biometrika 2000 87 2 329 343 2-s2.0-0001149964
41. O'Hagan A., Stevens J. W., On estimators of medical costs with censored data. Journal of Health Economics 2004 23 3 615 625 2-s2.0-2342567056 10.1016/j.jhealeco.2003.06.006 (Pubitemid 38569541)
42. Raikou M., McGuire A., Estimating medical care costs under conditions of censoring. Journal of Health Economics 2004 23 3 443 470 2-s2.0-2342460318 10.1016/j.jhealeco.2003.07.002 (Pubitemid 38569533)
43. Young T. A., Estimating mean total costs in the presence of censoring: a comparative assessment of methods. PharmacoEconomics 2005 23 12 1229 1242 2-s2.0-29144436367 10.2165/00019053-200523120-00007 (Pubitemid 41803319)
44. Basu A., Manning W. G., Estimating lifetime or episode-of-illness costs under censoring. Health Economics 2010 19 9 1010 1028 2-s2.0-77956637581 10.1002/hec.1640
45. Griffiths R. I., Barron R. L., Gleeson M. L., Granulocyte-colony stimulating factor (G-CSF) use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer (ESBC). PharmacoEconomics 2011 30 2 103 118
46. Xie J., Liu C., Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Statistics in Medicine 2005 24 20 3089 3110 2-s2.0-27144479267 10.1002/sim.2174 (Pubitemid 41489423)
47. Efron B., Tibshirani R. J., An Introduction to the Bootstrap (Monographs on Statistics and Applied Probability) 1994 Boca Raton, Fla, USA Chapman and Hall/CRC